SCHEMBL21991235

SCHEMBL21991235

CC(C)OC(=O)C(C)(C)Oc1ccc(Br)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 8/20 0.62
KMT2A Q03164 7/20 0.62
MEN1 O00255 6/20 0.62
MAPT P10636 5/20 0.62
CYP1A2 P05177 3/20 0.62
CYP3A4 P08684 3/20 0.62
NPSR1 Q6W5P4 3/20 0.62
PPARG P37231 3/20 0.62
LMNA P02545 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
ABCB11 O95342 2/20 0.62
TSHR P16473 2/20 0.62
HTR2A P28223 2/20 0.62
PMP22 Q01453 2/20 0.62
CYP2C19 P33261 2/20 0.62
MAPK1 P28482 2/20 0.62
USP2 O75604 1/20 0.62
ADORA3 P0DMS8 1/20 0.62
CYP2C9 P11712 1/20 0.62
ADRB3 P13945 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15363157 0.90 PPARA (0.53) PPARAKMT2AMEN1MAPTCYP1A2
Ethane SCHEMBL16527883 0.89 PPARA (0.52) PPARAKMT2AMEN1MAPTCYP1A2
SCHEMBL21991759 0.85 PPARA (0.64) PPARAKMT2AMEN1MAPTCYP1A2
SCHEMBL23605937 0.85 PPARA (0.64) PPARAKMT2AMEN1MAPTCYP1A2
SCHEMBL15363159 0.84 PPARA (0.48) PPARAKMT2AMEN1MAPTCYP1A2
SCHEMBL16528253 0.83 PPARA (0.47) PPARAKMT2AMEN1MAPTCYP1A2
SCHEMBL21991447 0.83 PPARA (0.62) PPARAKMT2AMEN1MAPTCYP1A2
SCHEMBL21992457 0.83 CNR1 (0.86) PPARAKMT2AMEN1MAPTCYP1A2
SCHEMBL28653724 0.83 PPARA (0.62) PPARAKMT2AMEN1MAPTCYP1A2
SCHEMBL27302986 0.83 PPARG (0.61) PPARAKMT2AMEN1MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119161239-A Fenofibrate in Process for the preparation of intermediates 山东新时代药业有限公司 2024-12-20 CN disclosed
US-20220409566-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-12-29 US disclosed
US-20220142961-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-05-12 US disclosed
US-11318111-B2 CCL5 inhibitors LAPKO INC (US) 2022-05-03 US disclosed
US-20210196665-A1 CCL5 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-07-01 US disclosed
US-10940132-B2 CCL5 inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-03-09 US disclosed
US-20200138766-A1 CCL5 INHIBITORS LAPKO INC. DBA AFECTA PHARMACEUTICALS 2020-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220142961-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 PPARA 806/4885KMT2A 4842/4885MEN1 3749/4885
US-20200138766-A1 CCL5 INHIBITORS CCL5, CCL11, CCR5 PPARA 806/4885KMT2A 4842/4885MEN1 3749/4885
US-20210196665-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 PPARA 806/4885KMT2A 4842/4885MEN1 3749/4885
US-10940132-B2 CCL5 inhibitors CCL5, CCL11, CCR5 PPARA 806/4885KMT2A 4842/4885MEN1 3749/4885
US-11318111-B2 CCL5 inhibitors CCL5, CCL11, CCR5 PPARA 806/4885KMT2A 4842/4885MEN1 3749/4885
US-20220409566-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 PPARA 806/4885KMT2A 4842/4885MEN1 3749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.